These data reflect a recent reduction in melanoma-related mortality due to the introduction of more efficacious therapeutic treatments, such as targeted therapy with BRAF and MEK inhibitors and the use of immunotherapy as the new standard of care for advanced melanoma stages [5,6]. The gene discussed is MAP2K7; the disease is melanoma.